Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF): Price and Financial Metrics

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF): $0.86

0.01 (+1.77%)

POWR Rating

Component Grades













Add CANF to Watchlist
Sign Up

Industry: Biotech



in industry


  • Growth is the dimension where CANF ranks best; there it ranks ahead of 72.14% of US stocks.
  • The strongest trend for CANF is in Momentum, which has been heading down over the past 70 days.
  • CANF ranks lowest in Momentum; there it ranks in the 8th percentile.

CANF Stock Summary

  • CANF's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 359.96 -- higher than 93% of US-listed equities with positive expected earnings growth.
  • The ratio of debt to operating expenses for Can-Fite BioPharma Ltd is higher than it is for about merely 5.6% of US stocks.
  • With a price/sales ratio of 573.8, Can-Fite BioPharma Ltd has a higher such ratio than 99.22% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Can-Fite BioPharma Ltd, a group of peers worth examining would be SNGX, VNE, VCNX, ARAV, and ORGS.
  • CANF's SEC filings can be seen here. And to visit Can-Fite BioPharma Ltd's official web site, go to

CANF Valuation Summary

  • CANF's price/earnings ratio is -29.9; this is 181.92% lower than that of the median Healthcare stock.
  • CANF's price/earnings ratio has moved down 25.2 over the prior 90 months.
  • Over the past 90 months, CANF's EV/EBIT ratio has gone down 25.8.

Below are key valuation metrics over time for CANF.

Stock Date P/S P/B P/E EV/EBIT
CANF 2021-08-31 565.3 71.0 -29.9 -29.9
CANF 2021-08-30 562.3 70.6 -29.7 -29.8
CANF 2021-08-27 569.9 71.6 -30.1 -30.2
CANF 2021-08-26 568.3 71.4 -30.0 -30.1
CANF 2021-08-25 562.3 70.6 -29.7 -29.8
CANF 2021-08-24 565.3 71.0 -29.9 -29.9

CANF Growth Metrics

    The 3 year price growth rate now stands at -95.35%.
  • Its 5 year price growth rate is now at -92.01%.
  • Its 4 year revenue growth rate is now at 333.42%.
CANF's revenue has moved down $1,269,000 over the prior 12 months.

The table below shows CANF's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2020-12-31 0.763 -12.063 -14.443
2019-12-31 2.032 -10.8 -9.587
2018-12-31 3.82 -4.155 -6.571
2018-12-31 3.82 -4.155 -6.571
2018-12-31 3.82 -4.155 -6.571
2017-12-31 0.79272 -8.93673 -4.67397

CANF's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CANF has a Quality Grade of C, ranking ahead of 37.52% of graded US stocks.
  • CANF's asset turnover comes in at 0.086 -- ranking 277th of 677 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows CANF's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.086 1 -12.110
2019-12-31 0.252 1 -5.082
2018-12-31 0.499 1 -2.980
2018-12-31 0.499 1 -2.980
2018-12-31 0.499 1 -2.980
2017-12-31 0.089 1 -3.771

CANF Stock Price Chart Interactive Chart >

Price chart for CANF

CANF Price/Volume Stats

Current price $0.86 52-week high $2.62
Prev. close $0.84 52-week low $0.78
Day low $0.83 Volume 123,182
Day high $0.89 Avg. volume 288,847
50-day MA $1.01 Dividend yield N/A
200-day MA $1.30 Market Cap 23.25M

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (CANF) Company Bio

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.

CANF Latest News Stream

Event/Time News Detail
Loading, please wait...

CANF Latest Social Stream

Loading social stream, please wait...

View Full CANF Social Stream

Latest CANF News From Around the Web

Below are the latest news stories about Can-Fite BioPharma Ltd that investors may wish to consider to help them evaluate CANF as an investment opportunity.

Dawson James Thinks Can-Fite BioPharma’s Stock is Going to Recover

Dawson James analyst Jason Kolbert maintained a Buy rating on Can-Fite BioPharma (CANF – Research Report) on January 31 and set a price target of $9.00. The company's shares closed last Tuesday at $1.09, close to its 52-week low of $0.94. According to, Kolbert is a 3-star analyst with an average return of 2.3% and a 39.2% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Can-Fite BioPharma with a $7.00 average price target.

Brian Anderson on TipRanks | February 9, 2022

Can-Fite begins enrollment in phase 2b trial of namodenoson to treat liver disease

Can-Fite BioPharma (CANF) enrolled the first patient in a phase 2b study of its drug namodenoson to treat non-alcoholic steatohepatitis ((NASH))

Seeking Alpha | January 31, 2022

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

PETACH TIKVA, Israel, January 31, 2022--Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

Yahoo | January 31, 2022

Can-Fite says Piclidenoson destroys pathological skin cells in vitro

Can-Fite BioPharma (CANF) announces that pre-clinical studies with skin cells, modeling psoriasis in humans, show that Piclidenoson destroys pathological skin cells.The

Seeking Alpha | January 13, 2022

Can Fite's Piclidenoson Destroys Pathological Skin Cells, Lab Study Shows

Can-Fite BioPharma Ltd (NYSE: CANF) announced preclinical studies with skin cells, modeling psoriasis in humans, showing that Piclidenoson destroys pathological skin cells. Piclidenoson is the company's lead drug candidate for the treatment of psoriasis. The company's scientists reported that in the cell culture of human HaCaT cells, incubated with Piclidenoson, cell apoptosis was induced with an increase in the caspase protein, known to mediate apoptotic responses. Related: Can-Fite Expects Dat

Yahoo | January 13, 2022

Read More 'CANF' Stories Here

CANF Price Returns

1-mo -7.71%
3-mo -25.54%
6-mo -29.96%
1-year -59.81%
3-year -71.33%
5-year -96.85%
YTD -33.33%
2021 -27.53%
2020 -46.06%
2019 -82.54%
2018 -14.86%
2017 -37.82%

Continue Researching CANF

Want to see what other sources are saying about Can-Fite BioPharma Ltd's financials and stock price? Try the links below:

Can-Fite BioPharma Ltd (CANF) Stock Price | Nasdaq
Can-Fite BioPharma Ltd (CANF) Stock Quote, History and News - Yahoo Finance
Can-Fite BioPharma Ltd (CANF) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1373 seconds.